# Abraham Bassan

> Abraham Bassan is a Series A investor at Samsara BioCapital backing Biotechnology and Medical. See 5 investments, check sizes, portfolio. Updated Aug 2026.

- Type: Angel Investor
- Fund: [Samsara BioCapital](https://shizune.co/investors/profile/samsara-biocapital)
- Location: San Francisco Bay Area, United States
- Total investments: 5
- Last investment: Dec 2025
- Lead investor: 20%
- Last updated: Aug 2026
- LinkedIn: https://www.linkedin.com/in/abraham-abe-bassan-08b05612/

Abraham Bassan is a Series A investor at Samsara BioCapital in San Francisco Bay Area focused on Biotechnology and Medical. Abraham Bassan is based out of San Jose, California and is the Partner of Samsara BioCapital and Board of Directors at Rani Therapeutics. Abraham previously worked at Revolution Medicines as a Director of Program Biology. Abraham Bassan attended the Princeton University.

## Investment focus

### Industry

| Industry | Investments | Share |
| --- | --- | --- |
| Biotechnology | 3 | 60% |
| Medical | 1 | 20% |
| Life Science | 1 | 20% |

### Stage

| Stage | Investments | Share |
| --- | --- | --- |
| Series A | 3 | 60% |
| Series B | 2 | 40% |

## Investments

| Company | Description | Amount | Stage | Date | Website |
| --- | --- | --- | --- | --- | --- |
| Link Cell Therapies | Link Cell Therapies develops engineered cell therapy technologies intended to create targeted CAR T-based treatments for cancer. The company applies proprietary logic-gating methods that require co-expression of multiple cancer antigens to activate therapeutic T cells, aiming to focus immune cell activity on tumor cells while reducing effects onnon-cancerous tissues. Its work spans programs for solid tumors and certain hematologic cancers, with lead candidates progressing through preclinical development and preparation for clinical research. Link Cell Therapies also explores additional platforms and therapeutic programs that build on its core targeting technology to expand applications of engineered cellular therapies. | $60M | Series A | Dec 15, 2025 |  |
| Septerna | Septerna is a biotechnology company. | $150M | Series B | Jul 11, 2023 |  |
| Septerna | Septerna is a biotechnology company. | $100M | Series A | Jan 27, 2022 |  |
| Graphite Bio | Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications totransform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. | $150.7M | Series B | Mar 15, 2021 |  |
| Graphite Bio | Graphite Bio is a clinical-stage, next-generation gene editing company harnessing high efficiency targeted gene integration to develop a new class of therapies to potentially cure a wide range of serious and life-threatening diseases. Graphite Bio is pioneering a precision gene editing approach that could enable a variety of applications totransform human health through its potential to achieve one of medicine’s most elusive goals: to precisely “find & replace” any gene in the genome. Graphite Bio’s platform allows it to precisely correct mutations, replace entire disease-causing genes with normal genes or insert new genes into predetermined, safe locations. | $45M | Series A | Sep 16, 2020 |  |

5 of 5 investments shown.

## Co-investors
- [Third Rock Ventures](https://shizune.co/investors/profile/third-rock-ventures) — VC Fund, 4 deals together
- [Versant Ventures](https://shizune.co/investors/profile/versant-ventures) — VC Fund, 4 deals together
- [Logos Capital](https://shizune.co/investors/profile/logos-capital) — VC Fund, 3 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/biotechnology-value-fund) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners) — VC Fund, 2 deals together
- [Biotechnology Value Fund](https://shizune.co/investors/profile/bvf-partners-3e10) — VC Fund, 2 deals together

## About Samsara BioCapital

VC Fund · Palo Alto, United States

Samsara Biocapital provides investment advisory services to help entrepreneurs turn their own ideas and visions into successful companies. Samsara BioCapital, as a results-driven organization, is always looking for ambitious and visionary partners with the drive and flexibility to take their company to the next level. Samsara BioCapital promotesbiotech innovation and collaborates with inspiring companies as they develop important and innovative new therapies.

5 contacts available at Samsara BioCapital.

| Name | Title | Profile |
| --- | --- | --- |
| Abraham Bassan | Partner | https://shizune.co/investors/profile/abraham-bassan |
| Michael Dybbs | Partner | https://shizune.co/investors/profile/mike-dybbs |
| Christian Richard | Head of Public Research | https://shizune.co/investors/profile/christian-m-richard |
| Marcos Milla | Venture Partner | https://shizune.co/investors/profile/marcos-milla |
| Srini Akkaraju | Founder | https://shizune.co/investors/profile/srini-akkaraju |

## Similar investors

### Similar stage
- [Antler](https://shizune.co/investors/profile/antler-be9c) — VC Fund
- [Alumni Ventures](https://shizune.co/investors/profile/alumni-ventures-group) — VC Fund
- [General Catalyst](https://shizune.co/investors/profile/general-catalyst-partners) — VC Fund

## FAQ

### What does Abraham Bassan invest in?

Abraham Bassan invests primarily in Biotechnology, Medical and Life Science startups, most often at Series A and Series B stage. Most of the 5 investments tracked by Shizune back companies in United States. The Investment Focus section breaks down every industry, stage and country in the portfolio.

### When did Abraham Bassan last invest?

The most recent investment recorded for Abraham Bassan closed in Dec 2025. Shizune tracks 5 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.

### Is Shizune's investor data accurate?

Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.

# About Shizune
Shizune.co is an investor database. Core features:
- 48,091 startup investors (angels, VCs, accelerators, and others)
- Email, phone, LinkedIn (for intros), socials, and other contact data
- Updated daily from public funding news
- CSV and Excel export

The User can access the full database FOR FREE after signing up: shizune.co